- No file added yet -
Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
Version 2 2023-06-15, 15:27
Version 1 2023-06-08, 11:22
media
posted on 2023-06-15, 15:27 authored by Adis Journals on behalf of:, Amy S. Paller, Carsten Flohr, Lawrence Eichenfield, Alan Irvine, Jamie Weisman, Jennifer Soung, Ana Pinto Correia, Chitra R. Natalie, Claudia Rodriguez Capriles, Evangeline Pierce, Sarah Reifeis, Renata Gontijo Lima, Clara Armengol Tubau, Vivian Laquer, Stephan Weidinger
Article full text
The above Video Abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. (see “read the peer-reviewed publication” opposite).
